Melanoma vaccine - Sanofi Genzyme

Drug Profile

Melanoma vaccine - Sanofi Genzyme

Alternative Names: Ad2CMV-gp100; Ad2CMV-MART1

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 May 2006 No development reported - Phase-II for Malignant melanoma in USA (Intradermal)
  • 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top